De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder
The Deciphering Developmental Disorders Study
(2019) American Journal of Human Genetics, volume 104, issue 4, pp. 709 - 720
(Article)
Abstract
The Mediator is an evolutionarily conserved, multi-subunit complex that regulates multiple steps of transcription. Mediator activity is regulated by the reversible association of a four-subunit module comprising CDK8 or CDK19 kinases, together with cyclin C, MED12 or MED12L, and MED13 or MED13L. Mutations in MED12, MED13, and MED13L were previously
... read more
identified in syndromic developmental disorders with overlapping phenotypes. Here, we report CDK8 mutations (located at 13q12.13) that cause a phenotypically related disorder. Using whole-exome or whole-genome sequencing, and by international collaboration, we identified eight different heterozygous missense CDK8 substitutions, including 10 shown to have arisen de novo, in 12 unrelated subjects; a recurrent mutation, c.185C>T (p.Ser62Leu), was present in five individuals. All predicted substitutions localize to the ATP-binding pocket of the kinase domain. Affected individuals have overlapping phenotypes characterized by hypotonia, mild to moderate intellectual disability, behavioral disorders, and variable facial dysmorphism. Congenital heart disease occurred in six subjects; additional features present in multiple individuals included agenesis of the corpus callosum, ano-rectal malformations, seizures, and hearing or visual impairments. To evaluate the functional impact of the mutations, we measured phosphorylation at STAT1-Ser727, a known CDK8 substrate, in a CDK8 and CDK19 CRISPR double-knockout cell line transfected with wild-type (WT) or mutant CDK8 constructs. These experiments demonstrated a reduction in STAT1 phosphorylation by all mutants, in most cases to a similar extent as in a kinase-dead control. We conclude that missense mutations in CDK8 cause a developmental disorder that has phenotypic similarity to syndromes associated with mutations in other subunits of the Mediator kinase module, indicating probable overlap in pathogenic mechanisms.
show less
Download/Full Text
Keywords: behavioral disorder, CDK8, congenital heart disease, de novo mutation, dominant negative, hypotonia, intellectual disability, kinase, Mediator complex, Mediator kinase modulopathy, Genetics(clinical), Genetics, Research Support, Non-U.S. Gov't, Journal Article
ISSN: 0002-9297
Publisher: Cell Press
Note: Funding Information: We are very grateful to all the families for their participation in this study. We thank Sue Butler for cell culture, Michael Carter for technical support, staff at the Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM) Sequencing facility for DNA sequencing, and Kirsty McWalter and Erin Torti (GeneDx) for their help with connecting clinical cases. The Deciphering Developmental Disorders (DDD) study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. The research team acknowledges the support of the National Institute for Health Research (NIHR), through the Comprehensive Clinical Research Network. This study makes use of DECIPHER, which is funded by the Wellcome Trust. T.K. was funded by the Cancer Research UK Accelerator Award C1362/A20263. M.J.O.R. J.B. and P.A.C. acknowledge support from Cancer Research UK; A.H. for post-doctoral funding from the Institute of Cancer Research (ICR); and O.P. for funding from Merck. A.O.M.W. was supported by the NIHR Oxford Biomedical Research Centre Programme and the Wellcome Investigator Award 102731. The views expressed in this publication are those of the authors and not necessarily those of Wellcome, NIHR, or the Department of Health. Funding Information: The Deciphering Developmental Disorders (DDD) study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003 ), a parallel funding partnership between Wellcome and the Department of Health , and the Wellcome Sanger Institute [grant number WT098051 ]. The research team acknowledges the support of the National Institute for Health Research (NIHR), through the Comprehensive Clinical Research Network . This study makes use of DECIPHER, which is funded by the Wellcome Trust . T.K. was funded by the Cancer Research UK Accelerator Award C1362/A20263 . M.J.O.R., J.B., and P.A.C. acknowledge support from Cancer Research UK ; A.H. for post-doctoral funding from the Institute of Cancer Research (ICR); and O.P. for funding from Merck . A.O.M.W. was supported by the NIHR Oxford Biomedical Research Centre Programme and the Wellcome Investigator Award 102731 . The views expressed in this publication are those of the authors and not necessarily those of Wellcome , NIHR , or the Department of Health . Publisher Copyright: © 2019 The Author(s)
(Peer reviewed)